Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Neukio Bio of Shanghai Raises $40 Million for Universal CAR-T Therapies

publication date: Jul 30, 2021

Neukio Biotherapeutics, a Shanghai startup, completed a $40 million Angel round to develop universal CAR-T therapies. The round was led by Lilly Asia Venture, with participation from IDG Capital and Sherpa Investments. Neukio is developing allogenic cell therapies from the iPSC-CAR-NK axis. The company combines in-house innovation and external collaboration with global partners. Dr. Richard Wang, Founder, Chairman and CEO of Neukio was previously CEO of Fosun Kite, where he oversaw China development of Kite's Yescarta, an autologous CAR-T therapy. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021